Physician

David B S Dyke, MD

According to 2025 Medicare claims, David Dyke, MD (NPI: 1346325172) practices advanced heart failure and transplant cardiology in the Detroit-Dearborn-Livonia, MI market, with the plurality of this provider's patient population coming from Wayne, MI. This provider's primary affiliated billing organization is REGENTS OF THE UNIVERSITY OF MICHIGAN (NPI: 1891205969; TIN: 386006309) and primary practice location at 48109-5000. Dyke is affiliated with the POM ACO (ACO ID: A1297) and McLaren High Performance Network, LLC (ACO ID: A3317), participating under the MSSP model.

Dyke's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 199 traditional Medicare patients, billed 460 HCPCS/CPT codes, and received $30,719 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 4,068 prescription claims across 290 beneficiaries totaling $3,955,140 in drug costs, led by Vyndamax (Tafamidis). DME data shows 303 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $45,110 to $30,719. In contrast, Part D prescription costs have moved sharply higher in recent years, from $235,358 to $3,955,140. For DME billing, this smaller-volume category fell sharply in recent years, from $2,661 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	260	867	$45,110
2016	266	963	$48,024
2017	244	1,031	$55,451
2018	306	972	$49,032
2019	262	776	$41,700
2020	248	618	$33,952
2021	249	490	$41,286
2022	221	385	$35,247
2023	236	408	$36,920
2024	199	460	$30,719

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	168	2,980	$235,358
2016	189	3,120	$291,092
2017	189	3,290	$303,337
2018	214	3,340	$338,370
2019	251	3,531	$415,873
2020	247	3,559	$843,919
2021	274	3,579	$816,781
2022	274	3,617	$1,163,847
2023	298	3,861	$1,712,472
2024	290	4,068	$3,955,140

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	75	790	$76,930
2016	80	729	$90,591
2017	67	754	$96,172
2018	65	814	$96,345
2019	52	668	$84,205
2020	32	569	$94,361
2021	31	570	$72,511
2022	27	410	$60,870
2023	22	416	$51,163
2024	N/R	303	$32,401

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	80	108	$108
93451	Insertion of tube in right heart chambers for measurement	47	53	$96
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	72	81	$73
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	22	26	$51
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	99	137	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Vyndamax	Tafamidis	118	3,540	$2,569,995
Vyndaqel	Tafamidis Meglumine	16	480	$346,136
Entresto	Sacubitril/Valsartan	209	14,856	$316,848
Jardiance	Empagliflozin	136	9,517	$171,897
Eliquis	Apixaban	112	8,173	$150,075

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	37	$18,299
J7527	Everolimus, oral, 0.25 mg	N	N/R	27	$9,351
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	77	$1,681
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	73	$1,355
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	25	$960

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for David B. S. Dyke, MD?

Tedicare shows public-source Medicare data for David B. S. Dyke, MD (NPI 1346325172), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does David B. S. Dyke, MD have ACO affiliation data?

David B. S. Dyke, MD is shown with ACO affiliation data for POM ACO (MSSP, ACO ID A1297) and McLaren High Performance Network, LLC (MSSP, ACO ID A3317).

What billing organization is linked to David B. S. Dyke, MD?

David B. S. Dyke, MD is linked to REGENTS OF THE UNIVERSITY OF MICHIGAN (billing NPI 1891205969) in the available physician profile data.

Does David B. S. Dyke, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.